Rosen Law Firm announced a class action lawsuit for purchasers of Aardvark Therapeutics, Inc. common stock issued in or traceable to the company’s February 13, 2025 initial public offering, as well as securities purchased between February 13, 2025, and May 14, 2026, inclusive. The lawsuit alleges that defendants made materially false or misleading statements and failed to disclose adverse information about ARD-101, including that the drug was less safe than represented and that its clinical, regulatory and commercial prospects were overstated. Investors who want to seek appointment as lead plaintiff must move the Court by October 13, 2026. No class has been certified, and investors may retain counsel, remain absent class members or take no action at this stage. Rosen Law Firm said eligible investors may participate through a contingency-fee arrangement without paying out-of-pocket fees or costs.